Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab plus corticosteroids as initial treatment for chronic graft-versus-host disease
NL-OMON60473Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing Axatilimab + corticosteroids with Placebo + corticosteroids (2 arms). Primary endpoint: Event-free survival. Started Aug 2025; status: recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NL-OMON60473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60473.